
export const EVT_CONTENT = {
  earlyEligible: "Class I recommendation: EVT strongly recommended for anterior circulation LVO (ICA/M1) with ASPECTS ≥6 in 0-6h window. Overwhelming evidence from multiple randomized controlled trials showing significant benefit. (2026 AHA/ASA Guidelines)",
  largeCore: "Class IIb: EVT MAY be considered for large cores (ASPECTS 3-5) in 0-6h window. SELECT2 and ANGEL-ASPECT trials showed benefit but with higher hemorrhage risk (15-20%). Individualized decision required. (2026 AHA/ASA Guidelines)",
  dawnEligible: "Class I recommendation: EVT based on DAWN criteria (clinical-core mismatch). Age, NIHSS, and core volume meet favorable profile for late-window (6-24h) intervention. Strong evidence of benefit. (2026 AHA/ASA Guidelines, reaffirmed from DAWN trial)",
  defuseEligible: "Class I recommendation: EVT based on DEFUSE-3 criteria (perfusion mismatch). Core <70 mL, mismatch volume ≥15 mL, and mismatch ratio ≥1.8 indicate substantial salvageable tissue. Strong evidence for benefit in 6-16h window. (2026 AHA/ASA Guidelines, reaffirmed from DEFUSE-3 trial)",
  largeCoreLate: "Class IIb: EVT MAY be considered for large cores (50-100 mL) in 6-24h window. SELECT2 and ANGEL-ASPECT trials showed possible benefit but with increased hemorrhage risk. Requires careful patient selection. (2026 AHA/ASA Guidelines)",
  notEligibleLate: "No target profile met for late-window EVT. Patient does not meet DAWN criteria (clinical-core mismatch) or DEFUSE-3 criteria (perfusion mismatch). Consider best medical therapy. (2026 AHA/ASA Guidelines)"
};

export const ELAN_CONTENT = {
  evidence: "Anticoagulation timing determined using evidence-based protocol. The ELAN trial showed early initiation was non-inferior and appeared safe compared to later initiation.",
  reference: "Paciaroni M et al. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation (ELAN Trial). NEJM 2023. Incorporated into AHA/ASA 2026 Guidelines for Secondary Stroke Prevention."
};

export const SE_CONTENT = {
  evidence: "Source: Glauser T et al. Epilepsy Curr 2016; Kapur J et al. N Engl J Med 2019 (ESETT Trial).",
  stage2Note: "The ESETT Trial found no significant difference in efficacy or safety between Fosphenytoin, Valproate, and Levetiracetam for benzodiazepine-refractory SE."
};

export const MIGRAINE_CONTENT = {
  evidence: "",
  triptan: "Sumatriptan 6 mg Subcutaneous",
  dhe: "Dihydroergotamine (DHE) IV"
};

export const GCA_CONTENT = {
  reference: "Based on 2021 ACR/Vasculitis Foundation guideline and 2023 EULAR imaging recommendations."
};
